Wyoming

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. A Wyoming-licensed clinician reviews it, in most cases asynchronously, since Wyoming permits telehealth providers to prescribe non-controlled medications like GLP-1s without requiring a live video visit. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Wyoming address — most patients in Cheyenne, Casper, and Laramie receive it within 2–3 business days; rural addresses may take an extra day.

The process is the same as for semaglutide — complete Pallas's online intake, and a Wyoming-licensed clinician reviews it, typically asynchronously since Wyoming permits telehealth prescribing of non-controlled medications like GLP-1s without a live video visit. If appropriate, your clinician can prescribe either compounded tirzepatide, prepared per-patient by a US-licensed §503A pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is legal and available to eligible Wyoming residents through licensed telehealth. It is prepared per-patient by US-licensed 503A and 503B compounding pharmacies under FDCA §503A, and a Wyoming-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas serves Wyoming with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes. Wyoming grants nurse practitioners full practice authority — prescriptive authority is part of the APRN license itself, and no collaborative agreement or physician supervision is required at any stage. A Wyoming-licensed nurse practitioner or physician can prescribe semaglutide and tirzepatide via telehealth once your intake is reviewed. Every Pallas clinician who treats Wyoming patients holds an active Wyoming license appropriate to their role.

Several licensed telehealth platforms serve Wyoming residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in Wyoming, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Wyoming residents.

No — Wyoming permits telehealth providers to establish the patient relationship and prescribe non-controlled medications like GLP-1s asynchronously, without a live video visit, when the standard of care is met. Your Pallas intake is reviewed by a Wyoming-licensed clinician by secure message; your clinician may still request a video visit or additional information if your history calls for it. You can complete the entire process from your phone or computer.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Wyoming address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Cheyenne, Casper, or a rural Wyoming ZIP code. Wyoming Medicaid covers GLP-1s for type 2 diabetes with prior authorization; coverage for weight-management indications is limited, and compounded GLP-1s are not covered.

Eligibility is always decided by a Wyoming-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Wyoming-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Wyoming-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Wyoming Board of Medicine reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Wyoming address, usually within 2–3 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team from the Pallas app or your patient portal, and change your plan or cancel anytime from the portal — no phone calls or retention hoops.

Many patients take a GLP-1 alongside metformin, statins, or blood pressure medication, and these are commonly used together under a clinician's supervision. Your Wyoming-licensed provider reviews your complete medication list during intake, including insulin or sulfonylureas, which can raise the risk of low blood sugar when combined with a GLP-1 and may call for a dose adjustment. List every medication and supplement you take so your clinician can confirm a GLP-1 is safe to add.

After your Wyoming-licensed provider approves your prescription, most patients start at the lowest dose, taken once weekly, with the dose increased gradually over the following weeks to reduce nausea and other GI side effects. Your care team checks in during this period to see how you're tolerating the medication and to answer questions by secure message. If you're not tolerating the starting dose well, your clinician can adjust your titration schedule before your next shipment ships to your Wyoming address.

Compounded semaglutide injection through Pallas is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Wyoming address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Wyoming address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® (pen or pill), Zepbound^® and Foundayo^™ for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Wyoming patients cash-pay: the daily Wegovy^® pill and Foundayo^™ are $299 for your first month, then $499 every 4 weeks, and the weekly pens start at $1,069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Wyoming during intake.

Coverage of GLP-1 medications for weight loss through Medicaid is limited. Wyoming Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Medicaid or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in Wyoming, and neither requires insurance. One: stay on FDA-approved Wegovy^® or Zepbound^® at flat cash-pay pricing from $1,069/mo. Two: if a clinician licensed in Wyoming determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Wyoming weighs your history, goals, and budget to recommend a starting point.

It depends on what you are comparing. Pallas is a cash-pay telehealth service that serves every ZIP code in Wyoming with one all-in plan price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. There is no separate membership fee, and nothing is charged until a clinician prescribes. No video visit is required in Wyoming. Before paying any service, check whether the quoted price includes the medication or is a membership billed on top of it, whether the company is LegitScript-certified, and whether you are charged before a clinician has prescribed.